Option Care Health, Inc. (NASDAQ:OPCH) Insider Sells $1,030,926.96 in Stock

Option Care Health, Inc. (NASDAQ:OPCH) insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Option Care Health Trading Up 1.4 %

NASDAQ:OPCH traded up $0.46 during trading hours on Monday, hitting $33.96. 1,699,328 shares of the company were exchanged, compared to its average volume of 1,584,820. The company has a fifty day simple moving average of $28.70 and a 200 day simple moving average of $28.06. Option Care Health, Inc. has a one year low of $21.39 and a one year high of $34.54. The stock has a market capitalization of $5.78 billion, a price-to-earnings ratio of 28.54, a price-to-earnings-growth ratio of 2.30 and a beta of 1.35. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77.

Wall Street Analyst Weigh In

OPCH has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $30.00 price objective (down from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the stock from $26.00 to $33.00 in a report on Monday, January 13th. UBS Group assumed coverage on shares of Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price objective for the company. The Goldman Sachs Group lowered shares of Option Care Health from a “buy” rating to a “neutral” rating and cut their target price for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Finally, Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and raised their price objective for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.88.

Hedge Funds Weigh In On Option Care Health

Hedge funds have recently made changes to their positions in the stock. Westfield Capital Management Co. LP increased its position in Option Care Health by 10.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after purchasing an additional 599,589 shares during the period. Global Alpha Capital Management Ltd. increased its position in shares of Option Care Health by 108.3% during the third quarter. Global Alpha Capital Management Ltd. now owns 49,818 shares of the company’s stock worth $1,559,000 after buying an additional 25,905 shares during the period. Graypoint LLC bought a new position in Option Care Health during the fourth quarter worth $1,161,000. Victory Capital Management Inc. lifted its holdings in Option Care Health by 4,432.8% in the third quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock valued at $50,756,000 after buying an additional 1,585,818 shares during the period. Finally, Barclays PLC lifted its holdings in Option Care Health by 180.1% in the third quarter. Barclays PLC now owns 310,194 shares of the company’s stock valued at $9,708,000 after buying an additional 199,454 shares during the period. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.